Survodutide vs Retatrutide
Both add glucagon receptor agonism to GLP-1 agonism. Retatrutide also adds GIP; survodutide does not.
Survodutide
A dual glucagon-receptor / GLP-1-receptor agonist being developed for obesity and metabolic liver disease (MASH).
BEST STUDIED FOR
Incretin & metabolic
Read the cited profile →
Retatrutide
Retatrutide (LY3437943) is a single peptide engineered to activate three receptors at once — GLP-1, GIP and glucagon.
BEST STUDIED FOR
Triple-agonist (GLP-1/GIP/glucagon) metabolic research
FREE GIFTFree GHK-Cu 50 mg with every Retatrutide 30mg vial and free GHK-Cu 100 mg with every Retatrutide 60mg vial, until 15 Oct — one per vial, added automatically at checkout.
Side by side · to buy
Price, purity and dispatch
| Compare | Survodutide | Retatrutide30 mg · more sizes |
|---|---|---|
| Price | — | fromR1,749 |
| Cost per mg | — | R58.3 / mg |
| Purity (Janoshik) | — | 99.676%HPLC, published |
| Stock | — | Restocking |
| Dispatch | — | When restocked |
| Certificate | — | View CoA → |
| Literature | — | 3 papers → |
| Research focus | Incretin & metabolic | Triple-agonist (GLP-1/GIP/glucagon) metabolic research |
| Read the cited profile | Notify me |
Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.
SIDE BY SIDE
| Survodutide | Retatrutide | |
|---|---|---|
| The key difference | GLP-1 + glucagon | GLP-1 + GIP + glucagon |
| Class | Incretin & metabolic | Incretin & metabolic |
| Mechanism | Modelled on oxyntomodulin, survodutide activates both the GLP-1 receptor (appetite, insulin) and the glucagon receptor (energy expenditure, hepatic fat metabolism) — the rationale for its liver-disease programme. | Retatrutide (LY3437943) is a single peptide engineered to activate three receptors at once — GLP-1, GIP and glucagon. |
| Status | Phase 2 in obesity and MASH (2024); phase 3 obesity results reported in 2026. Not yet approved. | Investigational triple agonist in phase 3 trials; not an approved medicine. |
| Reported safety signals | Trials report gastrointestinal events as the main tolerability issue, with dose-escalation studied to manage them. | Phase 2 trials reported mainly gastrointestinal adverse events and dose-related heart-rate increases. |
| A key study | Describes the discovery and preclinical pharmacology of survodutide as an oxyntomodulin-like dual agonist. (Mol Metab 2022, PMID 36356832) | In a phase-2 randomised trial, participants receiving retatrutide showed dose-dependent reductions in body weight over 48 weeks. (N Engl J Med 2023, PMID 37366315) |
WHEN TO RESEARCH WHICH
Comparing them helps separate the effect of the glucagon arm from that of the GIP arm. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Survodutide] BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy — Mol Metab 2022. PMID 36356832
- [Survodutide] Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial — Lancet Diabetes Endocrinol 2024. PMID 38330987
- [Survodutide] A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis — N Engl J Med 2024. PMID 38847460
- [Retatrutide] Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — N Engl J Med 2023. PMID 37366315
- [Retatrutide] Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Nat Med 2024. PMID 38858523
- [Retatrutide] Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression — NPJ Metab Health Dis 2025. PMID 40094000
FREQUENTLY ASKED
What is the difference between Survodutide and Retatrutide?
Both add glucagon receptor agonism to GLP-1 agonism. Retatrutide also adds GIP; survodutide does not.
What is the regulatory status of Survodutide and Retatrutide?
Survodutide: Phase 2 in obesity and MASH (2024); phase 3 obesity results reported in 2026. Not yet approved. Retatrutide: Investigational triple agonist in phase 3 trials; not an approved medicine.
What safety signals have been reported?
Survodutide: Trials report gastrointestinal events as the main tolerability issue, with dose-escalation studied to manage them. Retatrutide: Phase 2 trials reported mainly gastrointestinal adverse events and dose-related heart-rate increases.
Which studies is this comparison based on?
For Survodutide: “BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy” (PMID 36356832); “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial” (PMID 38330987); “A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis” (PMID 38847460). For Retatrutide: “Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial” (PMID 37366315); “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial” (PMID 38858523); “Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression” (PMID 40094000).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
Shop this comparison
Supplied for laboratory research only · not for human use